By Katherine Hamilton
Soleno Therapeutics gained approval from the Food and Drug Administration for its hyperphagia drug.
The biopharmaceutical company focused on treating patients with rare diseases said Wednesday it got approval for Vykat XR, which is intended to treat hyperphagia in adults and children over four years old with Prader-Willi syndrome.
Prader-Willi syndrome is a genetic disorder. A hallmark of the disease is hyperphagia, an intense and persistent sense of hunger.
Soleno expects the drug to be available in April, it said.
The approval was based on a study and safety data from a comprehensive clinical development program.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 26, 2025 17:28 ET (21:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.